PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24002703-5 2013 Doxycycline (10 mug/mL), an inhibitor of MMP, markedly attenuated the hypoxia-induced downregulation of Cx43 protein expression at 6 h. The hypoxia-induced decrease in Cx43 protein expression was significantly reversed by U0126 (10 muM), a MEK/ERK1/2 inhibitor, at 6 and 12 h; LY294002 (30 muM), a PI3K inhibitor, downregulated Cx43 expression. U 0126 222-227 matrix metallopeptidase 9 Homo sapiens 41-44 24504262-5 2014 U0126, an ERK1/2-specific inhibitor, blocked IL-7-induced cell migration and invasion, and also suppressed the expression of MMP-9 in the presence of IL-7. U 0126 0-5 matrix metallopeptidase 9 Homo sapiens 125-130 25033895-6 2014 Furthermore, MCP-1-induced secretion of MMP-9 was inhibited by U0126 (inhibitor of the ERK 1/2 pathway) and SB203580 (inhibitor of the p38 MAPK pathway), but not SP600125 (inhibitor of the JNK1/2 pathway). U 0126 63-68 matrix metallopeptidase 9 Homo sapiens 40-45 24002703-6 2013 Hypoxia-induced MMP-9 activation was inhibited by treatment with LY294002, U0126, and, most especially, U0126. U 0126 75-80 matrix metallopeptidase 9 Homo sapiens 16-21 24002703-6 2013 Hypoxia-induced MMP-9 activation was inhibited by treatment with LY294002, U0126, and, most especially, U0126. U 0126 104-109 matrix metallopeptidase 9 Homo sapiens 16-21 23770289-5 2013 Treatment with ERK1/2 inhibitor U0126 significantly inhibited induction of migration, MMP-9 expression, and activation of NF-kappaB and AP-1 in IL-5-treated cells. U 0126 32-37 matrix metallopeptidase 9 Homo sapiens 86-91 24039823-9 2013 Combined treatment with an ERK inhibitor (U0126) and baicalein resulted in a synergistic reduction in MMP-2, MMP-9 and u-PA expression and an increase in TIMP-1 and TIMP-2 expression; the invasive capabilities of MHCC97H cells were also inhibited. U 0126 42-47 matrix metallopeptidase 9 Homo sapiens 109-114 23114726-7 2013 The treatment of specific inhibitor for ERK (U0126) to MCF-7 cells could inhibit TPA-induced MMP-2/MMP-9 and phospho-ERK along with an inhibition on cell invasion and migration. U 0126 45-50 matrix metallopeptidase 9 Homo sapiens 99-104 23828593-8 2013 ERK1/2 inhibitor U0126 decreased the proliferation, and invasion of SGC7901 cells, and down-regulated the MMP-2 and MMP-9 activities. U 0126 17-22 matrix metallopeptidase 9 Homo sapiens 116-121 22461694-8 2012 Inhibition of MEK1/2 activity using PD98059 and U0126 reduced Fra-1 expression, DNA binding, MMP-9 promoter drive, and MMP-9 protein production. U 0126 48-53 matrix metallopeptidase 9 Homo sapiens 93-98 23353996-4 2013 To verify the regulatory mechanism of TPA-induced MMP-9 expression, we treated TPC-1 and MCF7 cells with the MEK1/2 inhibitor, UO126, and TPA-induced MMP-9 expression was significantly decreased. U 0126 139-144 matrix metallopeptidase 9 Homo sapiens 62-67 23353996-4 2013 To verify the regulatory mechanism of TPA-induced MMP-9 expression, we treated TPC-1 and MCF7 cells with the MEK1/2 inhibitor, UO126, and TPA-induced MMP-9 expression was significantly decreased. U 0126 139-144 matrix metallopeptidase 9 Homo sapiens 174-179 22710862-9 2012 Moreover, IL-5-stimulated MMP-9 expression was suppressed by the addition of U0126. U 0126 77-82 matrix metallopeptidase 9 Homo sapiens 26-31 22495096-9 2012 Blocking the mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK1/2) signaling by U0126 abrogated the CsA-induced increase in CXCL12 and CXCR4 expression and neutralizing antibodies to CXCL12 or CXCR4 completely inhibited the CsA-induced increase in cell number, invasion and MMP-9 and MMP-2 activity of cytotrophoblast. U 0126 110-115 matrix metallopeptidase 9 Homo sapiens 304-309 22543708-9 2012 The MAPK pathway inhibitors U0126 and PD98059 at the concentrations of 5 and 10 mumol/L inhibited invasion and metastasis of Bel-7402 cells induced by Shh, and decreased the expression of p-ERK1/2 and MMP-9. U 0126 28-33 matrix metallopeptidase 9 Homo sapiens 201-206 22461694-8 2012 Inhibition of MEK1/2 activity using PD98059 and U0126 reduced Fra-1 expression, DNA binding, MMP-9 promoter drive, and MMP-9 protein production. U 0126 48-53 matrix metallopeptidase 9 Homo sapiens 119-124 21276846-7 2011 In addition, ERK inhibitor (U0126) treated cells exhibited decreased MMP-9 activity in the zymographic assay. U 0126 28-33 matrix metallopeptidase 9 Homo sapiens 69-74 22033246-5 2012 In addition, EGF-induced MMP-9 expression was inhibited by UO126 (a MEK1/2 inhibitor) or SIS3 (a smad3 inhibitor), but not by SP600125 (a JNK inhibitor). U 0126 59-64 matrix metallopeptidase 9 Homo sapiens 25-30 20638679-13 2011 Inhibition of ERK (UO126) or p38 (SB203580), but not PI3K (LY294002 or wortmannin), blocked AGE-induced MMP-9 expression. U 0126 19-24 matrix metallopeptidase 9 Homo sapiens 104-109 22041445-19 2011 (5) The ERK inhibitor U0126 also significantly reduced the expression of EGF-induced MMP-9 (0.623+-0.030 vs. 2.112+-0.056, P<0.05) and NF-kappaB (0.325+-0.082 vs. 0.939+-0.153, P<0.05). U 0126 22-27 matrix metallopeptidase 9 Homo sapiens 85-90 22229442-6 2012 The stimulatory effect of AGE-BSA on MMP-9 was attenuated by inhibitors of extracellular-signal-regulated kinase (ERK1/2, U0126), p38 mitogen-activated protein kinase (MAPK, SB203580) and NF-kappaB, but not c-Jun N-terminal kinase. U 0126 122-127 matrix metallopeptidase 9 Homo sapiens 37-42 22229442-9 2012 We also observed the involvement of NF-kappaB in AGE-BSA-induced MMP-9 activation, which was not blocked by U0126 and SB203580. U 0126 108-113 matrix metallopeptidase 9 Homo sapiens 65-70 21963187-9 2011 The ERK inhibitor U0126, JNK inhibitor SP600125 and p38 MAPK inhibitor SB202190 all significantly decreased IL-beta-induced MMP-9 gene expression and pro MMP-9 in human primary amnion cells. U 0126 18-23 matrix metallopeptidase 9 Homo sapiens 124-129 21963187-9 2011 The ERK inhibitor U0126, JNK inhibitor SP600125 and p38 MAPK inhibitor SB202190 all significantly decreased IL-beta-induced MMP-9 gene expression and pro MMP-9 in human primary amnion cells. U 0126 18-23 matrix metallopeptidase 9 Homo sapiens 154-159 20458747-3 2010 Activation of extracellular signal-regulated kinase (ERK) and c-Jun-N-terminal kinase (JNK) by TPA was identified, and TPA-induced migration and MMP-9 activity was significantly blocked by ERK inhibitor PD98059 and U0126, but not JNK inhibitor SP600125. U 0126 215-220 matrix metallopeptidase 9 Homo sapiens 145-150 21167264-10 2011 However, when the cells were pretreated with inhibitors (5-aza-CdR or U0126) for 24h, the effects of arsenite on RECK, MMP-9, -2, uPA and VEGF expression were suppressed. U 0126 70-75 matrix metallopeptidase 9 Homo sapiens 119-124 18567920-9 2008 CypA-induced nuclear factor kappaB (NF-kappaB) activity for MMP-9 transcription were strongly blocked by extracellular signal-regulated kinase (ERK), c-Jun amino terminal kinase (JNK) inhibitors (U0126 and SP600125, respectively), but not by p38 mitogen-activated protein kinase (MAPK) inhibitors (SB203580). U 0126 196-201 matrix metallopeptidase 9 Homo sapiens 60-65 19924065-6 2009 TNF-alpha-induced MMP-9 expression was inhibited by the MEK1/2 specific inhibitor, UO126. U 0126 83-88 matrix metallopeptidase 9 Homo sapiens 18-23 19385051-12 2009 On the other hand, EGF-induced MMP-9 expression was decreased by the MEK1/2 inhibitor,UO126. U 0126 86-91 matrix metallopeptidase 9 Homo sapiens 31-36 19181503-5 2009 Interestingly, TPA-induced MMP-9 expression was significantly inhibited by UO126, but not by SP600125 and SB203580. U 0126 75-80 matrix metallopeptidase 9 Homo sapiens 27-32 18834856-6 2008 The specific MEK inhibitor, U0126, significantly blocks TRAIL-mediated NF-kappaB activation and subsequent MMP-9 induction. U 0126 28-33 matrix metallopeptidase 9 Homo sapiens 107-112 20492173-6 2010 Further, the treatment of specific inhibitor for ERK (U0126) to MCF-7 cells could inhibit TPA-induced MMP-2 and MMP-9 expressions along with an inhibition on cell invasion and migration. U 0126 54-59 matrix metallopeptidase 9 Homo sapiens 112-117 19715751-10 2009 In contrast, TPA-induced MMP-9 and COX-2 expression was decreased by UO126 (MEK 1/2 inhibitor). U 0126 69-74 matrix metallopeptidase 9 Homo sapiens 25-30 19616091-7 2009 IL-1 beta stimulated the transcriptional activity of wild-type MMP-9 promoter in A549 cells, which was inhibited by U0126, SB203580, SP600125, and helenalin. U 0126 116-121 matrix metallopeptidase 9 Homo sapiens 63-68 19616091-9 2009 Finally, the IL-1 beta-induced MMP-9 expression led to cell migration which was attenuated by pretreatment with U0126, SB203580, SP600125, helenalin, or MMP-2/9 inhibitor. U 0126 112-117 matrix metallopeptidase 9 Homo sapiens 31-36 19144181-8 2009 Transcript regulation of the cartilage-selective matrix genes Col2a1, Agc1 and Hapln1, and of the matrix metalloproteinase genes Mmp-12 and Mmp-9, were U0126 sensitive--whereas regulation of the inflammatory gene macrophage Csf-1 was U0126 insensitive. U 0126 152-157 matrix metallopeptidase 9 Homo sapiens 140-145 19052522-5 2008 Interestingly, TNF-alpha-induced MMP-9 activity and expression was decreased by UO126 and SB203580, but not by SP600125. U 0126 80-85 matrix metallopeptidase 9 Homo sapiens 33-38 16861876-10 2006 DCA-induced MMP-9 protein expression/activation was inhibited by pretreatment with SB203580, U0126, or PDTC. U 0126 93-98 matrix metallopeptidase 9 Homo sapiens 12-17 18336852-5 2008 Furthermore, the involvement of NF-kappaB in TNF-alpha-induced MMP-9 production was consistent with that TNF-alpha-stimulated degradation of IkappaB-alpha and translocation of NF-kappaB into the nucleus which were blocked by helenalin, but not by U0126 and SP600125, revealed by immunofluorescence staining. U 0126 247-252 matrix metallopeptidase 9 Homo sapiens 63-68 18336852-7 2008 MMP-9 promoter activity was enhanced by TNF-alpha in A549 cells transfected with wild-type MMP-9-Luc, which was inhibited by helenalin, U0126, or SP600125. U 0126 136-141 matrix metallopeptidase 9 Homo sapiens 0-5 18336852-7 2008 MMP-9 promoter activity was enhanced by TNF-alpha in A549 cells transfected with wild-type MMP-9-Luc, which was inhibited by helenalin, U0126, or SP600125. U 0126 136-141 matrix metallopeptidase 9 Homo sapiens 91-96 18357389-8 2008 The ERK1/2 inhibitor, U0126 and the p38 MAP kinase inhibitor, SB203580, significantly down-regulated TNF-alpha-induced MMP-9 expression and promoter activity. U 0126 22-27 matrix metallopeptidase 9 Homo sapiens 119-124 18024477-6 2008 The treatment of mitogen-activated protein kinase kinase (MEK) inhibitors (PD98059 and U0126) and LAB to HepG(2) cells could result in a synergistic reduction on the MMP-9 expression along with an inhibition on cell invasion. U 0126 87-92 matrix metallopeptidase 9 Homo sapiens 166-171 17311279-9 2007 MMP-9 promoter activity was enhanced by IL-1beta in HTSMCs transfected with MMP-9-Luc, which was inhibited by helenalin, U0126, SB202190, and SP600125. U 0126 121-126 matrix metallopeptidase 9 Homo sapiens 0-5 17311279-9 2007 MMP-9 promoter activity was enhanced by IL-1beta in HTSMCs transfected with MMP-9-Luc, which was inhibited by helenalin, U0126, SB202190, and SP600125. U 0126 121-126 matrix metallopeptidase 9 Homo sapiens 76-81 17234168-7 2007 In contrast inhibition of insulin"s "mitogenic" Ras-Raf-mitogen-activated protein kinase-kinase pathways with PD98059 (15 micromol/L) or U0126 (2 micromol/L) inhibited insulin-induced MMP-9 gelatinolytic activity in THP-1 cells. U 0126 137-142 matrix metallopeptidase 9 Homo sapiens 184-189 17276429-6 2007 Moreover, only ERK1/2 inhibition by U0126 suppressed PA-induced TNF-alpha production and MMP-9 expression. U 0126 36-41 matrix metallopeptidase 9 Homo sapiens 89-94 18345028-3 2008 We found that the highly selective MEK1/2 inhibitors U0126 and PD98059, and the expressed dominant-negative form of extracellular signal-regulated kinase (ERK), completely block Axl-mediated MMP-9 activation. U 0126 53-58 matrix metallopeptidase 9 Homo sapiens 191-196 17441962-5 2007 Moreover, Erk1/2 in CD147-overexpressing clones were observed to be highly activate and after treatment with U0126, an Erk1/2-specific inhibitor, the expression of MDR1, MMP2 and MMP9 were decreased significantly. U 0126 109-114 matrix metallopeptidase 9 Homo sapiens 179-183 16683234-7 2006 The MEK1/2 inhibitor U0126 completely inhibited LPS-induced MMP-9, which was partially inhibited by the p38 MAPK inhibitor SB203580. U 0126 21-26 matrix metallopeptidase 9 Homo sapiens 60-65 16356124-7 2005 Treatment of MCF10A cells with U0126, which is a pharmacological inhibitor of ERK1/2, reduced TPA-induced up-regulation of COX-2 and MMP-9. U 0126 31-36 matrix metallopeptidase 9 Homo sapiens 133-138 16266864-7 2005 Experiments using inhibitors of metabolic pathways (U0126, LY294002 and SN50) revealed that the secretion of MMP-9 was mediated through PI3/MEK1 kinases. U 0126 52-57 matrix metallopeptidase 9 Homo sapiens 109-114 15333786-9 2004 Interfering with either signalling pathway via PI3K inhibitor LY294002 or MEK inhibitor U0126 in EGF-stimulated HTR8/SVneo cells blocked the induction of MMP-9 and TIMP-1. U 0126 88-93 matrix metallopeptidase 9 Homo sapiens 154-159 15102045-8 2004 In addition, SB203580, U0126, and LY294002 significantly reduced the IL-1alpha or P. gingivalis-stimulated MMP-9 production, respectively (p < 0.05). U 0126 23-28 matrix metallopeptidase 9 Homo sapiens 107-112 15197768-9 2004 Selective inhibition of ERK/MAPK (by PD98059 or U0126) and PI3K (by LY294002 or wortmannin) led to marked reduction of both basal and BTC-induced MMP-9 activity and invasive ability of HNSCC cells. U 0126 48-53 matrix metallopeptidase 9 Homo sapiens 146-151 15132991-9 2004 However, treatment with U0126 (known as the ERKs inhibitor) or wortmannin (known as the PI-3K inhibitor), but not SB203580 (known as the p38 MAPK inhibitor), markedly inhibited the expression of MMP-9 induced by HBx in HBx-transfected cells. U 0126 24-29 matrix metallopeptidase 9 Homo sapiens 195-200 15102045-11 2004 SB203580, U0126, and LY294002 suppress MMP-9 production and/or activity and may therefore be valuable therapeutics in MMP-mediated periodontal destruction, and might be proved clinically useful agents, in combination with standard treatment modalities, in the treatment of periodontitis. U 0126 10-15 matrix metallopeptidase 9 Homo sapiens 39-44 12745093-3 2003 The PMA-induced MMP-9 secretion was abolished by treatment of a pan-protein kinase C (PKC) inhibitor, GF109203X, and an inhibitor of NF-kappaB activation, sulfasalazine, and partly inhibited by treatment of inhibitors of ERK pathway, PD98059 and U0126. U 0126 246-251 matrix metallopeptidase 9 Homo sapiens 16-21 14755547-6 2004 Treatment with U0126, an inhibitor of the extracellular signal-regulated kinase (ERK), significantly downregulated TNF-alpha-induced MMP-9 expression and promoter activity, whereas the inactive analog U0124 had no effect. U 0126 15-20 matrix metallopeptidase 9 Homo sapiens 133-138 15037119-6 2004 Intravitreal injection of IL-1 receptor antagonist (IL-1Ra) or MAP kinase inhibitor U0126 significantly decreased both ERK1/2 phosphorylation and MMP-9 induction suggesting that interruption of this cascade might attenuate retinal damage. U 0126 84-89 matrix metallopeptidase 9 Homo sapiens 146-151 14516792-7 2003 Gene and protein expression of other MMPs that regulate MMP-9, such as MMP-1 and MMP-13, were also up-regulated by TNF-alpha and inhibited by UO126, providing evidence that the MAPK pathway plays a fundamental role in the regulation of MMP-9 secretion by keratinocytes. U 0126 142-147 matrix metallopeptidase 9 Homo sapiens 56-61 14516792-7 2003 Gene and protein expression of other MMPs that regulate MMP-9, such as MMP-1 and MMP-13, were also up-regulated by TNF-alpha and inhibited by UO126, providing evidence that the MAPK pathway plays a fundamental role in the regulation of MMP-9 secretion by keratinocytes. U 0126 142-147 matrix metallopeptidase 9 Homo sapiens 236-241 19457446-6 2009 Further, the treatment of inhibitors specific for PI3K (Wortmannin) or ERK (U0126) to A549 cells could cause reduced activities of MMP-2, MMP-9, and u-PA. U 0126 76-81 matrix metallopeptidase 9 Homo sapiens 138-143 11888667-9 2002 Our data suggest that U0126 is an effective agent in inhibiting human A375 melanoma cell invasion and that the effect is partially due to the decreased production of uPA and MMP-9. U 0126 22-27 matrix metallopeptidase 9 Homo sapiens 174-179 11095246-6 2000 The addition of PD98059, U0126, and LY294002 in the presence of Epo restored MMP-9 production in UT-7 and CD36+ cells. U 0126 25-30 matrix metallopeptidase 9 Homo sapiens 77-82 12692261-8 2003 In addition, the expression and activity of MMP-1, MMP-2, and MMP-9 in MDR cells were decreased by treatment with U-0126, an inhibitor of mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/Erk). U 0126 114-120 matrix metallopeptidase 9 Homo sapiens 62-67 11467775-4 2000 Treatment of cells with MEK1 inhibitors, U0126 and PD98059, dramatically suppressed the secretion of MMP-9 activated by FN. U 0126 41-46 matrix metallopeptidase 9 Homo sapiens 101-106 30685603-8 2019 TNF-alpha significantly increased MMP-9 promoter activity and THP-1 cell adherence, and these effects were attenuated by pretreatment with quercetin, rottlerin, SP600125, U0126, tanshinone IIA or Bay 11-7082. U 0126 171-176 matrix metallopeptidase 9 Homo sapiens 34-39 29775175-5 2018 Inhibition of HIV-associated MAPK activation by U0126 abolishes NF-kappaB and MMP-9 upregulation and reduces HSV-1 spread. U 0126 48-53 matrix metallopeptidase 9 Homo sapiens 78-83 30613914-6 2019 Pretreatment with specific inhibitors of ERK1/2 (U0126), JNK (SP600125), and AP-1 (tanshinone IIA) attenuated IL-1beta-induced MMP-9 expression. U 0126 49-54 matrix metallopeptidase 9 Homo sapiens 127-132 28492136-5 2017 Afterward, treatment with the MEK1/2 inhibitor U0126 reduced the TGF-beta1-induced invasion and vimentin and MMP9 secretion in HepG2 cells, without affecting the inhibitory effects of TGF-beta1 on HepG2 cell proliferation. U 0126 47-52 matrix metallopeptidase 9 Homo sapiens 109-113 28959141-9 2017 h-TGF-beta1 stimulated Smad2/3 and ERK1/2 phosphorylation, and the MEK1/2 inhibitor U0126 attenuated TGF-beta1-induced KKU-M213 cell invasion and MMP-9 production but moderately enhanced the cytokine growth inhibitory activity. U 0126 84-89 matrix metallopeptidase 9 Homo sapiens 146-151 28344073-7 2017 The thrombin-induced MMP-9 release was inhibited by U0126, LY294002, Go6976, and Go6983. U 0126 52-57 matrix metallopeptidase 9 Homo sapiens 21-26 28560420-12 2017 Baicalein and U0126 markedly downregulated extracellular signal-regulated kinase 1/2, matrix metalloproteinase (MMP) 2 and MMP9 levels both in mRNA and protein. U 0126 14-19 matrix metallopeptidase 9 Homo sapiens 123-127 29190630-10 2017 Moreover, alpha-mangostin inhibited the expression of the MMP-9 mRNA levels as well as the activity of MMP-9 promoter, and these suppressive effects were further enhanced by U0126. U 0126 174-179 matrix metallopeptidase 9 Homo sapiens 58-63 27601158-7 2016 Moreover, BaP-induced overexpression of MMP9 and c-myc were attenuated by the ERK inhibitor U0126 and AhR inhibitor resveratrol, respectively. U 0126 92-97 matrix metallopeptidase 9 Homo sapiens 40-44 26241478-7 2015 Also, U0126 inhibited the elevated expression of MMP-2 and MMP-9 when they were treated with irisin. U 0126 6-11 matrix metallopeptidase 9 Homo sapiens 59-64 26293643-7 2016 Moreover, UCH-L1-overexpressing clones treated with U0126 (an Erk1/2-specific inhibitor) significantly decreased the expression of MDR1, CD147, MMP2, and MMP9. U 0126 52-57 matrix metallopeptidase 9 Homo sapiens 154-158 27042827-11 2016 Application of the MEK/ERK1/2 inhibitor U-0126 resulted in down-regulation of TNF-alpha-induced MMP9 secretion and abrogation of the enhanced concentration of proteases in the lipid rafts. U 0126 40-46 matrix metallopeptidase 9 Homo sapiens 96-100 26637807-8 2016 TGF-beta1-induced MMP-9 expression was decreased by both a MEK inhibitor, UO126, and a smad3 inhibitor, SIS3. U 0126 74-79 matrix metallopeptidase 9 Homo sapiens 18-23 26409848-9 2016 Eotaxin-1 induced up to 5.8 and 7.2-fold increases in the expression of MMP-9 mRNA and protein, respectively following 12h incubation with FLS, which was inhibited by antagonist of CCR3 SB328437 and an inhibitor of ERK U0126, indicating that action of eotaxin-1 on FLS seemed via CCR3 and ERK signaling pathway. U 0126 219-224 matrix metallopeptidase 9 Homo sapiens 72-77 25175278-8 2014 U0126 treatment suppressed the induction of MMP-9 expression through NF-kappaB binding activity in EPO gene transfectants. U 0126 0-5 matrix metallopeptidase 9 Homo sapiens 44-49 25550778-8 2014 Further investigation revealed that CD147 activated MAPK/ERK pathway, ERK inhibitor U0126 suppressed the CD147-induced cell invasion, migration and MMP-2, MMP-9 expression. U 0126 84-89 matrix metallopeptidase 9 Homo sapiens 155-160 24953855-6 2014 ERK inhibitor U0126 suppressed the migration, invasion, MMP-9 expression, and NF-kappaB binding activity in IL-15-treated 5637 cells. U 0126 14-19 matrix metallopeptidase 9 Homo sapiens 56-61 24789460-5 2014 The mechanisms were involved in upregulating MMP-9 expression through increasing AP-1 transcriptional activity via ERK1/2 pathway; these effects were dose-dependently inhibited by silencing ERK1/2 or using U0126. U 0126 206-211 matrix metallopeptidase 9 Homo sapiens 45-50